BRIEF-Com Hem Q1 operating profit increases
* Q1 revenue saw a increase of 37.7% to SEK 1,757m while organic revenue rose by 3.5% to SEK 1,321m.
Dec 15 Takara Bio :
* Says it signed an exclusive license agreement of Oncolytic virus HF10 with Otsuka Pharmaceutical
* Says it gives development and sale right of HF10 to Otsuka Pharmaceutical
Source text in Japanese: goo.gl/l0GBXC
Further company coverage: (Beijing Headline News)